secwatch.observer — SEC 8-K summary
======================================

Issuer:     KORU Medical Systems, Inc. (KRMD)
CIK:        0000704440
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001161697-24-000440
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KORU Medical Q3 revenue $8.2M (+17% YoY); raises FY 2024 guidance
-----------------------------------------------------------------

- Q3 net revenue $8.2M, up 17% YoY; gross margin 63.4%, up 140 bps from 62.0%.
- Core revenue $7.6M (+11% YoY); novel therapies $0.6M (+276% YoY).
- Net loss $1.6M ($0.03 diluted EPS); adjusted EBITDA loss $0.4M.
- Raises FY 2024 revenue guidance to $32.75-33.25M (15-17% growth) from $32.0-32.5M.
- Raises FY 2024 gross margin guidance to 62-63%; year-end cash guidance >$8.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/704440/000116169724000440/0001161697-24-000440-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/704440/000116169724000440/form_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001161697-24-000440

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer